Baseline Characteristics (Full Analysis Set, n = 354)
| Characteristic | Data | Characteristic | Data |
|---|---|---|---|
| Age (y) | 74 (43–91) | World Health Organization pain ladder | |
| EOG performance status | Step 1 (mild pain) | 243 (69%) | |
| 0 | 56 (16%) | Step 2 (moderate pain) | 74 (21%) |
| 1 | 204 (58%) | Step 3 (severe pain) | 37 (10%) |
| 2 | 61 (17%) | Prior bone health agents | |
| 3–4 | 27 (8%) | ≥1 medication | 45 (13%) |
| Missing | 6 (2%) | Denosumab | 19 (5%) |
| Months from diagnosis to initial visit | 55 (2–321) | Zoledronic acid | 25 (7%) |
| Months from bone metastases to initial visit | 28 (0–243) | Bisphosphonates | 1 (<1%) |
| Months from castration resistance to initial visit | 10 (0–155) | Prior radiotherapy | 194 (55%) |
| ALP (U/L) | Prior LPTs that ended before start of 223Ra* | ||
| Median | 133.0 | ≥1 | 219 (62%) |
| <150 | 134 (38%) | Docetaxel | 119 (34%) |
| 150–300 | 52 (15%) | Cabazitaxel | 29 (8%) |
| >300 | 44 (12%) | Abiraterone | 83 (23%) |
| Missing | 124 (35%) | Enzalutamide | 51 (14%) |
| PSA (μg/L) | Prior LPTs, including those overlapping 223Ra treatment† | ||
| Median | 58.0 | 0 | 112 (32%) |
| <50 | 118 (33%) | 1 | 119 (34%) |
| 50–200 | 70 (20%) | 2 | 65 (18%) |
| >200 | 61 (17%) | ≥3 | 58 (16%) |
| Missing | 105 (30%) | Opioid use before or at baseline | 116 (33%) |
| Extent of bone disease (n = 335) | |||
| <6 metastases | 37 (10%) | ||
| 6–20 metastases | 124 (35%) | ||
| >20 metastases | 127 (36%) | ||
| Superscan | 55 (16%) | ||
| Missing | 9 (3%) |